• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Penn State University - Developmental Therapeutics Review - Q4 2010 Product Image

Penn State University - Developmental Therapeutics Review - Q4 2010

  • ID: 1464072
  • December 2010
  • 69 pages
  • Global Markets Direct

Penn State University – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Penn State University – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Penn State University.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Penn State University with complete description READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Penn State University Snapshot
Penn State University Overview
Key Information
Key Facts
Penn State University – Research and Development Overview
Key Therapeutic Areas
Penn State University – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Penn State University – Pipeline Products Glance
Penn State University – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Penn State University Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Penn State University – Drug Profiles
Calfactant
Product Description
Mechanism of Action
R&D Progress
Pulmozyme
Product Description
Mechanism of Action
R&D Progress
Alli + Loestrin
Product Description
Mechanism of Action
R&D Progress
Bortezomib + (Carboplatin + Docetaxel)
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Vorinostat
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Cyclophosphamide + Non-Myeloablative Allogeneic Hematopoietic Transplantation
Product Description
Mechanism of Action
R&D Progress
Doxycycline for Diabetic Retinopathy (Penn State University)
Product Description
Mechanism of Action
R&D Progress
Interleukin-2 + Temozolomide
Product Description
Mechanism of Action
R&D Progress
Interleukin-2 + Temozolomide
Product Description
Mechanism of Action
R&D Progress
Metformin
Product Description
Mechanism of Action
R&D Progress
Monophasic oral gestodene + ethinyl estradiol
Product Description
Mechanism of Action
R&D Progress
Naltrexone
Product Description
Mechanism of Action
R&D Progress
Oncaspar + Doxil + Decadron
Product Description
Mechanism of Action
R&D Progress
Opioid Growth Factor
Product Description
Mechanism of Action
R&D Progress
Pasireotide Lar + Everolimus
Product Description
Mechanism of Action
R&D Progress
Prednisone
Product Description
Mechanism of Action
R&D Progress
RAD 001
Product Description
Mechanism of Action
R&D Progress
Viagra
Product Description
Mechanism of Action
R&D Progress
Vorinostat + Carboplatin + Etoposide
Product Description
Mechanism of Action
R&D Progress
[Met5]-enkephalin (Infusion of opioid growth factor )
Product Description
Mechanism of Action
R&D Progress
Capecitabine + Tarceva + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Clofarabine + Etoposide + Mitoxantrone
Product Description
Mechanism of Action
R&D Progress
Etoposide + Mitoxantrone + Clofarabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Opioid Growth Factor
Product Description
Mechanism of Action
R&D Progress
JVRS-100
Product Description
Mechanism of Action
R&D Progress
MAGE- A1 + MAGE- A3 + NY-ESO-1 Vaccine
Product Description
Mechanism of Action
R&D Progress
MAGE-A1 + MAGE-A3 + NY-ESO-1 peptides vaccine
Product Description
Mechanism of Action
R&D Progress
MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Product Description
Mechanism of Action
R&D Progress
MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine
Product Description
Mechanism of Action
R&D Progress
Vorinostat + (Paclitaxel + Bevacizumab + Carboplatin)
Product Description
Mechanism of Action
R&D Progress
Penn State University – Pipeline Analysis
Penn State University – Pipeline Products by Therapeutic Class
Penn State University Pipeline Products By Target
Penn State University – Pipeline Products by Route of Administration
Penn State University – Pipeline Products by Molecule Type
Penn State University - Dormant Projects
Penn State University – Locations And Subsidiaries
Head Office
Recent Developments
Apr 21, 2004: Opioid growth factor safe for treatment of pancreatic cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS